Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinovin With Isoflavones Alleviates BPH Symptoms - Study

This article was originally published in The Tan Sheet

Executive Summary

Novogen's Trinovin red clover isoflavone dietary supplement improves International Prostate Symptom Score (IPSS), nighttime urgency and overall symptoms of benign prostatic hyperplasia (BPH), University of Chicago researchers reported.

You may also be interested in...



Novogen's Promensil

Five-year-old Australian firm officially launching product containing 40 mg red clover-derived phytoestrogen isoflavones, designed for menopausal symptoms, at health food stores nationwide beginning April 7. The product was introduced in the U.S. on QVC March 8; Leiner has the electronic marketing rights to Promensil. During the last three months of 1997, the product had sales of $1.3 mil. in Australia; it has been available in the U.S. on very limited basis from physicians and is the company's inaugural dietary supplement. Novogen will spend $5 mil. on advertising and promotion, including print ads in women's books, as well as public relations, health seminars, medical journal ads and point-of-sale materials, according to promotional literature to the trade. Lally McFarland Pantello, New York City, is handling the advertising and Ruder, Finn, New York City, the PR. Novogen showed the product to over 24,000 registered health food/supplement store retailers March 13-15 at Natural Products Expo West in Anaheim, Calif...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS091339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel